A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1
Clinical trial NCT04250246 · UNKNOWN
Trial details
- NCT number
- NCT04250246
- Sponsor
- Italian Network for Tumor Biotherapy Foundation
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-01
- Primary completion
- 2023-03-01
- Enrollment
- 184
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.